Tina deVries
2022
In 2022, Tina deVries earned a total compensation of $561.5K as Former EVP, Research & Development at RVL Pharmaceuticals plc, a 19% decrease compared to previous year.
Compensation breakdown
| Salary | $147,462 |
|---|---|
| Other | $414,014 |
| Total | $561,476 |
deVries received $414K in other compensation, accounting for 74% of the total pay in 2022.
deVries also received $147.5K in salary.
Rankings
In 2022, Tina deVries' compensation ranked 4,169th out of 5,760 executives tracked by ExecPay. In other words, deVries earned more than 27.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,169 out of 5,760 | 28th |
Division Manufacturing | 2,356 out of 3,136 | 25th |
Major group Chemicals And Allied Products | 1,147 out of 1,422 | 19th |
Industry group Drugs | 1,077 out of 1,323 | 19th |
Industry Pharmaceutical Preparations | 788 out of 969 | 19th |
Source: SEC filing on April 24, 2023.
deVries' colleagues
We found three more compensation records of executives who worked with Tina deVries at RVL Pharmaceuticals plc in 2022.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019